Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.52IPCO.TO -0.15DC.A.TO 0.3NESN-SIX 0MCK 13.94GOOG -1.34XLV 0.79TEVA 0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.06
+0.09 (0.32%)
as of Aug 25, 2026, 2:11:02 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY ON WEAKNESS

Pfizer Inc(PFE)

Jan 18, 2023
It's been downgraded and shares have gone down. It's cheap enough now. Buy some now and buy more if the dividend rises back to 4% (at 3.6% now). Their pipeline looks promising.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$45.00

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 12, 2023
(A Top Pick Jan 12/22, Down 15%) 11x forward PE. Outperforming S&P since early 2021. Healthy drug pipeline. Still sees 30B USD in sales for Covid vaccines and treatment. Defensive and steady growth. Weak relative to market in January, an opportunity. Yield is 3.5%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$47.48

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 09, 2022
Monday they hold an analysts meeting to discuss their drug pipeline. Their biggest problem is that the street thinks there isn't much more to this company than its Covid franchise. Untrue! They've made enough acquisitions and invested in their pipeline to keep making new drugs.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$51.72

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 23, 2022
Sell PFE to buy MRK? Likes and owns them both. MRK is more in the immuno oncology and cancer space, whereas PFE is more diversified. Defensive and growth characteristics. MRK hit a new high today. PFE hasn't done as well, but has performed over the last 2 years. Own both for different reasons. May want to trim in early part of next cycle. Yield is 3.3%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$48.78

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 12, 2022
It has always been part of their health care portfolio. It is losing some lustre and interest created by Covid but is still a good health care company with a good dividend. He likes others as well, maybe a bit better.
Photo of Robert LauzonRobert Lauzon
Owned
Unlock Rating
$47.76

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Sep 08, 2022
When you're looking at pharma companies, you want to see the breadth of drugs that are in the pipeline, and any blockbuster drugs in there. You're also looking for dividends. Yield is 3.4%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$46.79

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 01, 2022
PFE vs. JNJ Coin flip. Both are stable for the long run. PFE is slightly cheaper right now.
Photo of Jason MannJason Mann
Owned
Unlock Rating
$46.48

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 10, 2022
Always a wall of worry around drug pricing, but rarely does it have a large impact. He sold this name after record revenues from vaccine news. He likes AZN, which is getting approval after approval. Another one is LLY, focusing on its diabetes and weight loss drug.
Photo of Jamie Murray Jamie Murray
No
Unlock Rating
$49.52

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 15, 2022
Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron.
Photo of Jason Snipe, CIO, Odyssey Capital AdvisorsJason Snipe, CIO, Odyssey Capital Advisors
Owned
Unlock Rating
$51.75

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 21, 2022
The entire drug sector hasn't been investable since the 1990s, because governments control drug prices and patent expiries. Pfizer is struggling to replace drugs coming off patent, like their cholesterol drug. It's really tough. It's a defensive sector, so the drug companies will hold up better and offer dividend growth.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$48.11

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Jun 14, 2022
(A Top Pick Apr 19/22, Down 3.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has triggered its stop at $48. To remain disciplined we recommend covering the position at this time.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$47.70

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 08, 2022
Results highly influenced by Covid vaccine. Earnings might be stagnant going forward. His choice is MRK, reasonable and sustainable multiple of 12x and very good dividend. MRK's major drug is patent-protected until at least 2026, plus great drugs in pipeline.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$53.65

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

May 26, 2022
(A Top Pick Apr 19/22, Up 9.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend trailing up the stop (from $42) to $48.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$54.09

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 12, 2022
Diversified business, gold standard. PFE is making acquisitions, building out the pipeline from Covid cashflow wins. Good mRNA franchise, benefits of diversity, plus management team executing on pipeline of acquisitions.
Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$49.01

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 10, 2022
(A Top Pick May 28/20, Up 45%) A defensive. Back then, they were working on the vaccine and luckily theirs was the most effective. He trimmed at $55, but still likes and holds it. The company has in the past struggled to build a pipeline of drugs. This morning they announced they will buy a company that treats migraines. They're spending $11 billion on their pipeline, which is promising. They earned $25 billion revenues in vaccines in 2021. Pays a great dividend. Remains a core holding.
Photo of Robert LauzonRobert LauzonUnlock Rating
$49.16

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 136 to 150 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.87$101
TFPM 0$
OGC.TO -0.31$42.91
SLB -0.3$53.7
ARG.TO 0.39$8.61

Today's Top Picks

SII.TO 3.52$190.71
IPCO.TO -0.15$35.07
DC.A.TO 0.3$5.45
NESN-SIX 0$
MCK 13.94$887.73

Popular Articles

Latest Sell Signals

RKLB -1.15$67.13
INTC 0.47$87.73
MSFT 2.5$489.81
WSP.TO -2.54$189.74
CLS.TO 7.17$414.53

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like